Introduction: AI as a part of everyday work in pharma
AI has been discussed in pharma for years, but until recently, it was mostly limited to research and early-stage discovery.
What we see now is different. AI is moving closer to everyday operations – into areas like Medical Affairs, commercial strategy, and internal analytics. Not as a separate innovation track, but as a tool teams actually use in their daily work.
This shift is happening for a simple reason. The amount of data in pharma keeps growing, while the time available to make decisions does not.
Teams work with clinical data, real-world evidence, physician feedback, internal reports, and external research. A lot of this information is valuable, but hard to use in practice because it is scattered, unstructured, or locked inside specific systems.
At the same time, expectations are increasing:
faster time to market
controlled R&D costs
better patient outcomes
These goals are not new, but the gap between what is expected and how work is actually done is becoming more visible. This is where AI starts to bring practical value.
Persistent challenges that slow down operations
Let's have a look at the problems teams deal with every day. These challenges are well known inside the industry, but they are difficult to solve with traditional approaches.
Fragmented and underutilized data
Data in pharma is spread across systems and formats. According to PRNewswire, citing research by the medical AI platform Emtelligent, over 80% of healthcare data is unstructured – from clinician notes and PDFs to reports and field insights. This is especially visible in physician interactions, where valuable feedback is captured in free-text formats and remains hard to analyze at scale.
Low R&D productivity
Drug development remains slow, expensive, and uncertain. In their article, McKinsey notes that bringing a new drug to market can cost up to $2.8 billion and take around 12 years, while only about 13% of candidates progress from Phase 1 to launch.
Patient recruitment challenges in clinical trials
Recruiting enough patients on time remains one of the biggest bottlenecks in clinical research. Most trials fail to meet enrollment targets, causing delays in study timelines and driving up costs. These delays can cascade through the development process, slowing proof-of-concept studies, regulatory submissions, and ultimately the launch of new therapies.
Supply chain instability and stock‑outs
Pharma supply chains are complex, with multiple tiers, strict temperature requirements, expiry constraints, and regulatory rules. This often leads to stock‑outs and excess inventory, increasing costs and affecting patient access to therapies.
Regulatory and compliance requirements
Pharma operates under strict regulatory frameworks, where data quality, traceability, and auditability are mandatory. These requirements increase process complexity and limit how quickly new approaches can be introduced.
These challenges are part of everyday work, and they explain why companies increasingly turn to AI to improve operational efficiency.
How AI can address these challenges
AI is increasingly applied in pharma to tackle operational bottlenecks, extract value from underutilized data, optimize R&D, streamline clinical trials, and improve supply chain performance. Its core capabilities include predictive analytics, large language models (LLMs), knowledge graphs, data integration, workflow automation, and real-time operational insights. Below are the main areas where AI brings measurable impact.
Data structuring and integration
AI transforms fragmented information into a usable format. NLP and large language models extract key details from clinical notes, lab results, and reports. Knowledge graphs and multimodal models link these datasets into a unified semantic layer.
As a result, teams across R&D, medical, and commercial functions can access consistent insights, turning previously hidden data into actionable intelligence.
R&D acceleration
AI models support target identification, in-silico screening, and de-novo design – helping teams identify promising biological targets, test molecules virtually, and generate new candidates. Portfolio prioritization and study design optimization help reduce the cost per asset.
By accelerating proof-of-concept studies, AI shortens development timelines and increases the chance of successful drug launches (as noted by McKinsey).
Clinical trial support
AI algorithms help identify and stratify patients using EHRs, registries, and claims data. They assist in selecting study sites, designing adaptive protocols, and predicting recruitment timelines.
This reduces delays, minimizes protocol amendments, and ensures studies proceed according to plan.
Pharmacovigilance automation
NLP and LLMs extract key fields from safety reports and documents. They help prioritize incoming cases, automatically fill required fields, and generate draft safety reports for regulatory submission, reducing manual work and speeding up processing.
This reduces manual effort, accelerates case processing, and allows safety teams to focus on critical tasks.
Supply chain optimization
Machine Learning models predict demand based on seasonality, epidemiology, and payer behavior. They optimize inventory levels and redistribution across warehouses and regions.
This decreases stock-outs, reduces excess inventory, and improves operational efficiency.
Real-world insights extraction
LLM and NLP systems analyze unstructured feedback from physicians, patients, and field teams. They detect sentiment, unmet clinical needs, and gaps in the evidence base.
This enables better-targeted educational initiatives, supports new research, and informs product strategy.
Case example: advanced AI solution for Medical Affairs analytics
In conversations with pharma teams, one challenge comes up again and again.
A large part of their work depends on interactions with physicians – discussions, feedback, questions, objections. All of this is captured after meetings, usually in CRM systems. But in practice, this data is hard to use. It sits in free-text notes, spread across teams and regions, and doesn’t easily translate into clear insights.
The result is simple: teams collect a lot of information, but struggle to see patterns behind it.
A similar situation occurred at AstraZeneca, a global biopharmaceutical company. During early discussions, it became clear that hundreds of field specialists were documenting insights every day, but analyzing them required manual effort. There was no easy way to understand what was happening across regions or how perceptions were changing over time. At the same time, strict data privacy requirements meant that any solution had to work within a secure internal environment.
At ZONE3000, we proposed an AI-based approach and quickly built a working demo. It showed that unstructured CRM data could be processed automatically, with relevant signals extracted and grouped into meaningful patterns. The concept proved practical and was developed into a full-scale solution.
At its core, the system focused on a few key capabilities:
extracting key themes and adoption barriers from free-text CRM entries
grouping similar signals into consistent categories
visualizing how these patterns evolve over time
generating short summaries to support preparation before meetings
The solution was deployed in a secure cloud environment with strict data protection controls, ensuring compliance with internal and regulatory requirements. As a result, a previously manual process became continuous and scalable.
Teams gained a clearer view of what was happening in the field, could react faster, and started making decisions based on aggregated insights rather than isolated inputs.
The future of AI in pharma
The AI landscape in the pharmaceutical and healthcare sectors is expanding rapidly. According to BCC Research (Nov 2025), the global AI market in pharma is estimated at $3.8 billion in 2025, with projections reaching $15.2 billion by 2030. In parallel, a joint EY‑Parthenon and Microsoft report notes that AI‑driven medical devices are expected to grow to about $97.07 billion by 2028.
The potential economic impact is equally significant. McKinsey, in its report “Scaling gen AI in the life sciences industry,” estimates that generative AI alone could create $60–110 billion in annual value across pharmaceutical and medical products, boosting productivity, speeding up drug discovery, and supporting clinical, manufacturing, and commercial operations.
Key areas of transformation
Over the next five years, the main areas of AI-driven development in pharma will continue to be those we discussed above:
Accelerated drug discovery: AI will identify new molecules and therapeutic targets more quickly and accurately, reducing the time and cost of early-stage research.
Optimized clinical trials: Patient selection, outcome prediction, and trial timelines will be improved with AI, helping to minimize delays and costs.
Smart manufacturing: Production will become more efficient and consistent with automation, real-time process monitoring, and predictive maintenance.
Regulatory Compliance: AI will significantly streamline document analysis and automated report preparation, speeding up approvals and reducing manual effort.
However, adopting AI in pharma requires a thoughtful approach. Success depends not only on the technology itself but also on how it is integrated into daily operations, data infrastructure, and organizational processes.
Five pillars for successful AI adoption
Based on our experience and industry research, I can highlight five key pillars for effective AI implementation in pharma:
Integrate AI algorithms into daily business processes to enable teams to make faster, data-driven decisions in real time.
Build scalable and reliable technology infrastructure that can support growing AI workloads and evolving analytical needs.
Maintain high-quality, structured, and well-prepared data to ensure AI models generate accurate and actionable results.
Train employees for new roles where AI becomes a collaborator, helping interpret insights and guiding strategic actions.
Establish strong governance around AI ethics, cybersecurity, and regulatory compliance to minimize risks and maintain trust.
Conclusion
The role of AI in pharma will only continue to grow, creating new opportunities for efficiency, insight, and innovation. So, no matter the size or scale of your company, now is the time to start exploring AI adoption. The key is to understand where AI can have the most impact within your own operations, identify which investments will truly add value, and move forward with confidence.
Companies that take this step today will be better positioned to accelerate decision-making, optimize processes, and stay ahead in an increasingly competitive landscape.
